These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 29634905

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Identification of a small molecule that increases hemoglobin oxygen affinity and reduces SS erythrocyte sickling.
    Nakagawa A, Lui FE, Wassaf D, Yefidoff-Freedman R, Casalena D, Palmer MA, Meadows J, Mozzarelli A, Ronda L, Abdulmalik O, Bloch KD, Safo MK, Zapol WM.
    ACS Chem Biol; 2014 Oct 17; 9(10):2318-25. PubMed ID: 25061917
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.
    Oksenberg D, Dufu K, Patel MP, Chuang C, Li Z, Xu Q, Silva-Garcia A, Zhou C, Hutchaleelaha A, Patskovska L, Patskovsky Y, Almo SC, Sinha U, Metcalf BW, Archer DR.
    Br J Haematol; 2016 Oct 17; 175(1):141-53. PubMed ID: 27378309
    [Abstract] [Full Text] [Related]

  • 5. New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo?
    Oder E, Safo MK, Abdulmalik O, Kato GJ.
    Br J Haematol; 2016 Oct 17; 175(1):24-30. PubMed ID: 27605087
    [Abstract] [Full Text] [Related]

  • 6. Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease.
    Schroeder P, Fulzele K, Forsyth S, Ribadeneira MD, Guichard S, Wilker E, Marshall CG, Drake A, Fessler R, Konstantinidis DG, Seu KG, Kalfa TA.
    J Pharmacol Exp Ther; 2022 Mar 17; 380(3):210-219. PubMed ID: 35031585
    [Abstract] [Full Text] [Related]

  • 7. Design, Synthesis, and Evaluation of Allosteric Effectors for Hemoglobin.
    Enakaya NA, Jefferson A, Chew-Martinez D, Matthews JS.
    Acc Chem Res; 2023 Jun 06; 56(11):1279-1286. PubMed ID: 36946781
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Nitric oxide reduces sickle hemoglobin polymerization: potential role of nitric oxide-induced charge alteration in depolymerization.
    Ikuta T, Thatte HS, Tang JX, Mukerji I, Knee K, Bridges KR, Wang S, Montero-Huerta P, Joshi RM, Head CA.
    Arch Biochem Biophys; 2011 Jun 01; 510(1):53-61. PubMed ID: 21457702
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Structural basis for the potent antisickling effect of a novel class of five-membered heterocyclic aldehydic compounds.
    Safo MK, Abdulmalik O, Danso-Danquah R, Burnett JC, Nokuri S, Joshi GS, Musayev FN, Asakura T, Abraham DJ.
    J Med Chem; 2004 Sep 09; 47(19):4665-76. PubMed ID: 15341482
    [Abstract] [Full Text] [Related]

  • 12. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin.
    Henry ER, Metaferia B, Li Q, Harper J, Best RB, Glass KE, Cellmer T, Dunkelberger EB, Conrey A, Thein SL, Bunn HF, Eaton WA.
    Blood; 2021 Sep 30; 138(13):1172-1181. PubMed ID: 34197597
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Rational modification of vanillin derivatives to stereospecifically destabilize sickle hemoglobin polymer formation.
    Deshpande TM, Pagare PP, Ghatge MS, Chen Q, Musayev FN, Venitz J, Zhang Y, Abdulmalik O, Safo MK.
    Acta Crystallogr D Struct Biol; 2018 Oct 01; 74(Pt 10):956-964. PubMed ID: 30289405
    [Abstract] [Full Text] [Related]

  • 16. In vitro effects of NIPRISAN (Nix-0699): a naturally occurring, potent antisickling agent.
    Iyamu EW, Turner EA, Asakura T.
    Br J Haematol; 2002 Jul 01; 118(1):337-43. PubMed ID: 12100171
    [Abstract] [Full Text] [Related]

  • 17. FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice.
    Shrestha A, Chi M, Wagner K, Malik A, Korpik J, Drake A, Fulzele K, Guichard S, Malik P.
    Blood Adv; 2021 May 11; 5(9):2385-2390. PubMed ID: 33944896
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin.
    Safo MK, Kato GJ.
    Hematol Oncol Clin North Am; 2014 Apr 11; 28(2):217-31. PubMed ID: 24589263
    [Abstract] [Full Text] [Related]

  • 19. Crystallographic analysis of human hemoglobin elucidates the structural basis of the potent and dual antisickling activity of pyridyl derivatives of vanillin.
    Abdulmalik O, Ghatge MS, Musayev FN, Parikh A, Chen Q, Yang J, Nnamani I, Danso-Danquah R, Eseonu DN, Asakura T, Abraham DJ, Venitz J, Safo MK.
    Acta Crystallogr D Biol Crystallogr; 2011 Nov 11; 67(Pt 11):920-8. PubMed ID: 22101818
    [Abstract] [Full Text] [Related]

  • 20. Increasing haemoglobin oxygen affinity to prevent sickling: abnormal haemoglobin variants as models.
    Franklin IM, Huehns ER, Rosemeyer MA.
    Br J Haematol; 1986 Oct 11; 64(2):319-29. PubMed ID: 3778826
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.